Our Values
Innovation, Collaboration, and Hope
Outsmarting cancer, together
Omico is a nationwide network of research and treatment centres that facilitates, supports and promotes clinical trials in genomic cancer medicine. Central to this is the use of molecular screening for the prevention and treatment of cancer.
Our Mission
Recent News
Making a difference
3000 patients enrolled onto the Molecular Screening and Therapeutics (MoST) program, 1000 people have enrolled in the Genetic Cancer Risk in the Young (RisC) study and 95 people have joined the Surveillance study in Multi-Organ Cancer prone syndromes (SMOC+) - great news for cancer research.
Masterclass webinar series - Demystifying the Molecular Tumour Board
Learn how members of a Molecular Tumour Board (MTB) come together to discuss and interpret tumour molecular profiles in the clinical context, recommending therapeutic strategies for the care of patients with cancer. 4 webinars on 29th Oct, 5th, 12th and 19th Nov 2020, 4 - 5pm
How cancer develops resistance to treatment
The cells of the human body are constantly dividing, and each time need to copy a three billion-letter DNA code with high precision to ensure cell survival. The same is not true for cancers, researchers have discovered.